Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and…
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July24, 2023(GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: ADCT), today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA ®(loncastuximab tesirine-lpyl), which is seeking an indication for the treatment of adult patients with relapsed or refractory (r/r) diffuse...
Nasdaq GlobeNewswire
24/07/2023
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
Tuebingen , Germany and Houston , TX ,July24 , 2023–Immatics N.V.(NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that Bristol Myers Squibb (NYSE: BMY) has made a $35 million equity investment in Immatics. Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.46 1...
Nasdaq GlobeNewswire
24/07/2023
Ultrasound Devices and Accessories Industry Banks on Transducers for Diagnostic…
In February 2023, GE Healthcare announced the purchase of an AI-enabled ultrasound company Caption Health to help in early disease detection and ultrasound scans. These trends have validated the valuation of the ultrasound device market size at USD 10.2 billion in 2022, poised to witness a 4.3% CAGR from 2023 through 2030. Soaring demand for point-of-care ultrasound devices, along with the penetration of AI technology, will augment the market revenue. InFebruary 2023, GE Healthcare announced...
PR Newswire
24/07/2023
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update…
MAINZ, Germany , July 24, 2023(GLOBE NEWSWIRE)– BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2023 on Monday, August 7 th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2023. To access the live conference...
Nasdaq GlobeNewswire
24/07/2023
Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar…
The CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is expected by the end of September 2023. The CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is expected by the end ofSeptember 2023. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: " We are very pleased to receive a positive opinion from the European Medicines...
PR Newswire
24/07/2023
Medical Device Cleaning Market to be Worth $47.3 Billion by 2030: Grand View…
Read full market research report, "Medical Device Cleaning Market Size, Share & Trends Analysis Report By Device (Non-critical, Semi-critical, Critical), By Technique (Cleaning, Disinfection), By EPA Classification, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read full market research report, " Medical Device Cleaning Market Size, Share & Trends Analysis Report By Device (Non-critical, Semi-critical, Critical), By Technique (Cleaning…
PR Newswire
24/07/2023
Neurointerventional Devices Market to Reach $5.3 Billion, Globally, by 2032 at…
Request Sample of the Report on Neurointerventional Devices Market Analysis 2032- Allied Market Research- https://www.alliedmarketresearch.com/request-sample/14825 Request Sample of the Report on Neurointerventional Devices Market Analysis 2032- Allied Market Research-https://www.alliedmarketresearch.com/request-sample/14825 Prime determinants of growth The growth of the neurointerventional devices market is fueled by the increasing prevalence of neurological disorders, a...
PR Newswire
24/07/2023
Orthopedic 3D Printing Devices Market to Gather $5.3 Billion, Globally, by 2032…
Request Sample of the Report on Orthopedic 3D Printing Devices Market Forecast 2032- Allied Market Research- https://www.alliedmarketresearch.com/request-sample/111743 Request Sample of the Report on Orthopedic 3D Printing Devices Market Forecast 2032- Allied Market Research-https://www.alliedmarketresearch.com/request-sample/111743 Prime Determinants of Growth In the last few years, there has been a steady increase in the development of healthcare infrastructure across the...
PR Newswire
24/07/2023
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars…
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in generic and innovative medicines and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that they have agreed to expand their existing strategic partnership agreement. Teva will also acquire subordinated convertible bonds to be issued by Alvotech.The partners...
Nasdaq GlobeNewswire
24/07/2023
Apollo leads India's Solid Multi-Organ Transplantation with over 23000…
Dr. Prathap C Reddy, Founder Chairman, Apollo, said, "We see this milestone as a testament to the advancement of clinical excellence practices we have built in India, with care and technology at the core. As we strive to keep our population healthy, we will continue to remain committed to bringing world-class care to everyone." Dr. Prathap C Reddy, Founder Chairman, Apollo, said,"We see this milestone as a testament to the advancement of clinical excellence practices we have built…
PR Newswire
24/07/2023
Orexo's patent win for ZUBSOLV® appealed
Nikolaj Sørensen, President and CEO of Orexo AB, said: "The decision from the District Court was very well motivated and clearly outlined the significant shortfalls in SUN's non-infringement and invalidity claims against the ZUBSOLV® patents. We remain very confident in the strength of the patent portfolio and that the Court of Appeals will come to the same conclusion." Nikolaj Sørensen, President and CEO of Orexo AB, said: "The decision from the District Court was very well…
PR Newswire
24/07/2023
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar…
If approved, will be first-of-a-kind biosimilarnatalizumab in Europe,for use in all indications of reference biologicPositive CHMP opinion based on evidence from extensive analytical characterization confirming similarity of biosimilar with reference biologic, in addition to Phase I and confirmatory Phase III studies in RRMS patientsSandoz is committed to accelerating access to potentially life-changing treatments, while generating savings for health systems and patients...
Nasdaq GlobeNewswire
24/07/2023
Daewoong Pharmaceutical's Fexuprazan takes its first step into Africa Entering…
Cooper Pharma, founded in 1933, has rapidly expanded its businesses in the pharmaceutical industry, keeping its number one ranking position in Morocco's PPI market, which was estimated to be around KRW75.5 billion in revenue last year. Daewoong intends to propose a new innovative solution to GERD drugs building on Cooper Pharma's significant market dominance and network. Cooper Pharma, founded in 1933, has rapidly expanded its businesses in the pharmaceutical industry, keeping its number one...
PR Newswire
24/07/2023
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder
Data published inNeuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, July 24 , 2023 - Addex T herapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that administration of a metabotropic...
Nasdaq GlobeNewswire
24/07/2023
Philips delivers improved operational performance driven by sales growth and…
Second-quarter highlightsGroup sales increased to EUR 4.5 billion, with 9% comparable sales growthIncome from operations amounted to EUR 221 million, compared to EUR 11 million in Q2 2022Adjusted EBITA increased to EUR 453 million, or 10.1% of sales, compared to EUR 216 million, or 5.2% of sales, in Q2 2022Order book continued to grow year-on-year, while comparable order intake declined following a high order intake in Q2 2022Operating cash flow improved to EUR 135 million,...
Nasdaq GlobeNewswire
24/07/2023
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi…
Partnership combines Roche's proven track record of successfully developing and launching innovative medicines worldwide with Alnylam's leadership in RNAi therapeuticsZilebesiran , a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide...
Nasdaq GlobeNewswire
24/07/2023
Ipsen announces a simplification of the concert of its principal shareholders…
PARIS, FRANCE, 24 July 2023– Ipsen (Euronext: IPN: ADR: IPSEY) announced today that the Board of Directors of Ipsen has been informed of certain changes of the shareholders' agreements relating to the concert of its principal shareholders. The shareholders' agreement 1made on December 19, 2019, between Highrock (controlled by Mrs. Anne Beaufour), Beech Tree (controlled by Mr. Henri Beaufour), MR BMH as well as MR Schwabe, FinHestia, Finvestan and Finveska (controlled by the Schwabe...
Nasdaq GlobeNewswire
24/07/2023
Bavarian Nordic Provides Update on RSV Vaccine Program
Phase 3 study failed to meet one of the success criteria of the primary objectiveRSV program to be discontinuedCOPENHAGEN, Denmark, July 22, 2023– Bavarian Nordic A/S (OMX: BAVA) today announced that its Phase 3 clinical trial of MVA-BN ®RSV, a respiratory syncytial virus (RSV) vaccine candidate for adults ≥60 years of age did not meet all the primary endpoints of preventing lower respiratory tract disease (LRTD) from RSV.The final study results showed that the vaccine candidate...
Nasdaq GlobeNewswire
22/07/2023
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of…
The CHMP opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorization for human medicines throughout the European Union (EU). If approved, Stemline and its affiliates will commercialize the product within Europe. ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations. ESR1 mutations are acquired mutations that develop as a result of exposure to endocrine therapy…
PR Newswire
21/07/2023
Humanized Mouse and Rat Model Market worth $349 million | MarketsandMarkets
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955 Browse in-depth TOC on "Humanized Mouse and Rat Model Market" 140 - Tables 27 - Figures 188 - Pages Humanized Mouse and Rat Model Market Scope: The genetic models dominated the humanized mouse and rat model market in 2022. Based on type, the humanized mouse...
PR Newswire
21/07/2023
Flow Cytometry Market size worth $ 7,384.22 Million, Globally, by 2030 at 7.75%…
Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=26644 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=26644 Browse in-depth TOCon" Flow Cytometry Market " 202 - Pages 126 – Tables 37 – Figures Flow Cytometry Market: Growing Prevalence of Chronic Diseases and Technological Advances Drive Demand In cell analysis and diagnostics, flow cytometry, a laser-based method used to assess cellular and...
PR Newswire
21/07/2023
Biomanufacturing Viral Detection and Quantification Market worth $981.41 Million…
Viral detection and quantification play an essential role in biomanufacturing, particularly when viruses are active ingredients. Biomanufacturing viral detection and quantification is a process of analyzing and determining the amount or concentration of viruses in the context of large-scale production of biological materials such as vaccines, therapeutic proteins or viral vectors. It ensures the consistency, quality and safety of the final product. Methods used to detect and quantify viral…
PR Newswire
21/07/2023
CHMP recommends Roche's Evrysdi for babies under two months old with spinal…
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority of Evrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months' treatment 1,2 If approved by the European Commission, Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globally...
Nasdaq GlobeNewswire
21/07/2023
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay®…
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS)Negative opinion from Committee for Orphan Medicinal Products (COMP) recommending not to maintain orphan drug designation for treatment of ALGSIpsen to appeal negative COMP opinion, which might delay final European Commission decisionApproval already granted by U.S. FDA in June 2023 for the treatment of cholestatic pruritus in...
Nasdaq GlobeNewswire
21/07/2023
Altri Comunicati
